fectiveness of delivery. While it minimizes immunotoxicity and other undesired side effects. The Company has licenced its technology to Alnylam and Merk&Co with the former providing royalty bearing access to some of its partners. TKMR has an ongoing research relationship with Bristol-Myers Squibb Compa